- Home
- ATXS vs SIGA Comparison
ATXS vs SIGA Comparison
Compare ATXS & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- SIGA
- Stock Information
- Founded
- ATXS 2008
- SIGA 1995
- Country
- ATXS United States
- SIGA United States
- Employees
- ATXS N/A
- SIGA N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- ATXS Health Care
- SIGA Health Care
- Exchange
- ATXS Nasdaq
- SIGA Nasdaq
- Market Cap
- ATXS 401.2M
- SIGA N/A
- IPO Year
- ATXS 2015
- SIGA 1997
- Fundamental
- Price
- ATXS $5.40
- SIGA $5.48
- Analyst Decision
- ATXS Strong Buy
- SIGA
- Analyst Count
- ATXS 5
- SIGA 0
- Target Price
- ATXS $26.60
- SIGA N/A
- AVG Volume (30 Days)
- ATXS 285.8K
- SIGA 452.4K
- Earning Date
- ATXS 03-11-2025
- SIGA 03-11-2025
- Dividend Yield
- ATXS N/A
- SIGA 10.89%
- EPS Growth
- ATXS N/A
- SIGA N/A
- EPS
- ATXS N/A
- SIGA 0.82
- Revenue
- ATXS N/A
- SIGA $138,719,350.00
- Revenue This Year
- ATXS N/A
- SIGA $35.56
- Revenue Next Year
- ATXS N/A
- SIGA N/A
- P/E Ratio
- ATXS N/A
- SIGA $6.68
- Revenue Growth
- ATXS N/A
- SIGA N/A
- 52 Week Low
- ATXS $5.24
- SIGA $5.16
- 52 Week High
- ATXS $13.33
- SIGA $12.83
- Technical
- Relative Strength Index (RSI)
- ATXS 30.54
- SIGA 42.96
- Support Level
- ATXS $5.89
- SIGA $5.55
- Resistance Level
- ATXS $6.52
- SIGA $6.04
- Average True Range (ATR)
- ATXS 0.37
- SIGA 0.25
- MACD
- ATXS -0.07
- SIGA -0.01
- Stochastic Oscillator
- ATXS 7.80
- SIGA 18.84
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.